Skip to content
value.today

Amplyx Pharmaceuticals, Inc.

Total raised
$117 M
3 rounds on record
Latest round
$91 M
Jul 2017
First round on record
Aug 2015
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Amplyx Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2017$91 MNo. 3$50 to $250 million

Amplyx Pharmaceuticals, Inc.: Raise no. 3, Jul 2017

Investors in this round

28 investors had bought by the notice of Jan 9, 2020: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$91 M of $103 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alan Fuhrman · Executive Officer
  • Ciara Kennedy · Executive Officer, Director
  • Mike Hodges · Executive Officer
  • Anand Mehra · Director
  • Edward Mathers · Director
  • Elaine Heron · Director
  • Johan Kordel · Director
  • Michael Grey · Director
  • Niall ODonnell · Director
  • Paul Grint · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ciara Kennedy, Ph.D., President and CEO. Source: SEC Form D and 1 amendment, newest notice filed Jan 9, 2020. Read the notice at the SEC.

equitySEC
Oct 2015$24 MNo. 2$10 to $50 million

Amplyx Pharmaceuticals, Inc.: Raise no. 2, Oct 2015

Investors in this round

25 investors had bought by the notice of Dec 24, 2015: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$24 M of $49 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ciara Kennedy · Executive Officer
  • Michael Grey · Executive Officer, Director
  • Mitchell Mutz · Executive Officer
  • Ed Mathers · Director
  • Elaine Heron · Director
  • Niall ODonnell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Amount Sold includes amounts paid pursuant to conversion of indebtedness.”

Signed by Michael Grey, President & CEO. Source: SEC Form D and 1 amendment, newest notice filed Dec 24, 2015. Read the notice at the SEC.

equitySEC
Aug 2015$2 MNo. 1Under $2 million

Amplyx Pharmaceuticals, Inc.: Raise no. 1, Aug 2015

Investors in this round

13 investors had bought by the notice of Aug 18, 2015: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$50,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Mitchell Mutz · Executive Officer, Director
  • Chrysa Mineo · Director
  • Elaine Heron · Director
  • Jack Florio · Director
  • Karen Talmadge · Director
  • Santosh Vetticaden · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Consists of Convertible Promissory Notes convertible into shares of Preferred Stock of the issuer.”

Signed by Mitchell Mutz, President. Source: SEC Form D, newest notice filed Aug 18, 2015. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Amplyx Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2020).

    SEC Form D · Jan 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jan 2020

That is all the official record says: Amplyx Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

No investor of Amplyx Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Amplyx Pharmaceuticals, Inc.
NameRoleNamed in
Alan FuhrmanExecutive officerJan 2020
Ciara KennedyExecutive officerJan 2020
Mike HodgesExecutive officerJan 2020
Michael GreyExecutive officerAug 2017
Mitchell MutzExecutive officerDec 2015
Anand MehraDirectorJan 2020
Ciara KennedyDirectorJan 2020
Edward MathersDirectorJan 2020
Elaine HeronDirectorJan 2020
Johan KordelDirectorJan 2020
Michael GreyDirectorJan 2020
Niall ODonnellDirectorJan 2020
Paul GrintDirectorJan 2020
Johan K?rdelDirectorAug 2017
Ed MathersDirectorDec 2015
Chrysa MineoDirectorAug 2015
Jack FlorioDirectorAug 2015
Karen TalmadgeDirectorAug 2015
Mitchell MutzDirectorAug 2015
Santosh VetticadenDirectorAug 2015

About

Company in San Diego, United States.